Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Evercore ISI Group維持對avidity biosciences的跑贏市場評級,將價格目標下調至53美元。
Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price target from $54 to $53.
Evercore ISI分析師Josh Schimmer維持對Avidity Biosciences (納斯達克:RNA)的推薦評級爲Outperform,並將價格目標從54美元下調至53美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。